{"id":"NCT02873221","sponsor":"Allergan","briefTitle":"An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine","officialTitle":"A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2016-09-13","primaryCompletion":"2018-08-02","completion":"2018-08-02","firstPosted":"2016-08-19","resultsPosted":"2019-08-28","lastUpdate":"2019-08-28"},"enrollment":1254,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Migraine, With or Without Aura"],"interventions":[{"type":"DRUG","name":"Ubrogepant","otherNames":[]},{"type":"DRUG","name":"Placebo-matching Ubrogepant","otherNames":[]},{"type":"DRUG","name":"Usual Care","otherNames":[]}],"arms":[{"label":"Usual Care","type":"ACTIVE_COMPARATOR"},{"label":"Ubrogepant 50 mg","type":"EXPERIMENTAL"},{"label":"Ubrogepant 100 mg","type":"EXPERIMENTAL"}],"summary":"This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.","primaryOutcome":{"measure":"Percentage of Participants With at Least 1 Treatment Emergent Adverse Event","timeFrame":"56 Weeks","effectByArm":[{"arm":"Usual Care","deltaMin":65,"sd":null},{"arm":"Ubrogepant 50 mg","deltaMin":66.3,"sd":null},{"arm":"Ubrogepant 100 mg","deltaMin":72.6,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":2},"locations":{"siteCount":177,"countries":["United States"]},"refs":{"pmids":["35977836","34874514"],"seeAlso":["http://www.allerganclinicaltrials.com"]},"adverseEventsSummary":{"seriousAny":{"events":17,"n":417},"commonTop":["Upper respiratory tract infection","Nasopharyngitis","Sinusitis","Urinary tract infection","Influenza"]}}